Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: Thirteen analysts give Aardvark a consensus rating of "Moderate Buy" (1 sell, 4 hold, 7 buy, 1 strong buy) with an average 12‑month target of $22.60.
• Market snapshot: the stock opened around $3.77, has a 52‑week range of $3.35–$17.94, a market cap of ~$82.3M and a negative P/E (‑1.29), highlighting a large gap to analyst targets and elevated risk.
• Business and recent results: Aardvark is a clinical‑stage biotech developing selective RORγ inverse agonists for autoimmune diseases; it reported quarterly EPS of ($0.81) (in line with estimates) and has drawn small new institutional positions.

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $22.60.

Several equities research analysts recently issued reports on AARD shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Aardvark Therapeutics in a report on Friday. BTIG Research reiterated a "buy" rating and issued a $9.00 price target on shares of Aardvark Therapeutics in a research report on Tuesday, March 24th. B. Riley Financial began coverage on shares of Aardvark Therapeutics in a research note on Wednesday, January 28th. They issued a "buy" rating and a $32.00 price objective for the company. William Blair started coverage on shares of Aardvark Therapeutics in a research report on Friday, December 12th. They set an "outperform" rating on the stock. Finally, Royal Bank Of Canada cut shares of Aardvark Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their target price for the company from $18.00 to $6.00 in a research note on Monday, March 2nd.

Hedge Funds Weigh In On Aardvark Therapeutics

Several large investors have recently made changes to their positions in AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Aardvark Therapeutics in the second quarter worth about $42,000. China Universal Asset Management Co. Ltd. bought a new stake in Aardvark Therapeutics during the 4th quarter valued at approximately $47,000. Persistent Asset Partners Ltd purchased a new position in Aardvark Therapeutics in the 4th quarter worth approximately $56,000. New York State Common Retirement Fund purchased a new position in Aardvark Therapeutics in the 2nd quarter worth approximately $99,000. Finally, MetLife Investment Management LLC bought a new position in Aardvark Therapeutics in the 4th quarter worth approximately $102,000.

Aardvark Therapeutics Stock Performance

NASDAQ:AARD opened at $3.77 on Wednesday. The stock has a 50-day simple moving average of $9.42 and a two-hundred day simple moving average of $11.53. The firm has a market capitalization of $82.26 million and a PE ratio of -1.29. Aardvark Therapeutics has a 52-week low of $3.35 and a 52-week high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.